



BJCN ANNUAL ASSEMBLY 2026 17th National Scientific Oncology Conference MORE

Management of Hepatocellular Carcinoma

Structures and Functions in the Bulgarian National Hub of the Mission Against Cancer

1 – 4 October 2026, Sofia

SCIENTIFIC PROGRAM

1 October 2026, Thursday

15:00 – 15:15 Official Opening

15:15 – 15:40 SPECIAL THEMATIC MODULE

Clinical Immuno-oncology in Gastrointestinal Neoplasms – A Vertical Perspective

Keynote lecture: *Prof. Dr. Nikolay Tsonev*

15:45 – 16:45 Symposium, supported by industry – *MSD*

Immunotherapy in gastrointestinal oncology: the role of Pembrolizumab

Moderator: *Dr. Radoslav Mangalzhiev*

Pembrolizumab in the treatment of metastatic gastric carcinoma

Prof. Dr. Nikolay Tsonev

The Place of *Pembrolizumab* in the Management of MSI-H/dMMR Colorectal Tumors

Dr. Bozhidar Murdjev

16:50 – 19:30 Symposium, supported by industry – *Miscellaneous*

Chair: *Assoc. Prof. Dr. Dimitar Kalev*

16:50 – 17:10 Company presentation – *Novartis*

Moderator: *Assoc. Prof. Dr. Asya Konsulova*

Risk, Evidence and Clinical Judgment: The Modern Path to Therapeutic Decision in HR+/HER2- Early-Stage Breast Cancer

Dr. Dimo Manov

Dr. Daniel Velez

17:10 – 17:30 Company presentation – *Pfizer*

When biology guides the choice: personalized approaches in mHR+/HER2- mBC and mCRPC

Dr. Radoslav Mangalzhiev

17:30 – 17:50 Company presentation – *Roche*

Tecentriq + Avastin – a therapeutic combination proven in real clinical practice in the treatment of advanced hepatocellular carcinoma

Dr. Marcela Koleva

**17:50 – 18:10 Company presentation – Bayer**

Personalizing treatment in mHSPC: optimizing effectiveness and quality of life with NUBEQA

Prof. Dr. Nikolay Tsonev

18:10 – 18:30 Company presentation – Astellas

Long-term benefits with Xtandi in mCSPC

Dr. Galina Dimitrova

18:30 – 18:50 Company presentation – Pierre Fabre

A mutation that doesn't wait: why the first move matters in BRAF V600E-mutated mCRC

Dr. Marcella Koleva

18:50 – 19:10 Company presentation – Johnson & Johnson

Erleada (apalutamide) in metastatic hormone-sensitive/androgen-pathway-modulated prostate cancer (mHSPC/APMS)

Dr. Radoslav Mangaldzhiev

19:10 – 19:30 Company presentation – AbbVie

Experience with *mirvetuximab soravtansine* from real clinical practice

Dr. Adriana Andreeva

20:00 Cocktail Reception**2 October 2026, Friday****08:30 – 10:10 FIRST PLENARY SESSION****Models of carcinogenesis and prevention of hepatocellular carcinoma (HCC)**

Chair: *Acad. Prof. Dr. Draga Toncheva*

08:30 – 08:45 Molecular mechanisms of hepatic carcinogenesis

Acad. Prof. Dr. Draga Toncheva

08:50 – 09:05 Molecular changes in the precancerous stage of virus- and alcohol-induced HCC

DSc Lyubomir Balabanski

09:10 – 09:25 Correlations of HBV/HCV- and *H. pylori*-infections with HCC – opportunities for primary prevention.

Prof. Dr. Petko Karagyzov, Dr. Kalina Panova

09:30 – 09:45 Barriers in the follow-up of patients with HCC and with chronic liver diseases

Dr. Galabina Hinkova

09:50 – 10:05 Tumor markers in HCC – from AFP to multimarker panels

Dr. Veselina Koleva

10:10 – 10:30 Coffee break**10:30 – 12:10 SECOND PLENARY SESSION****Imaging and morphological models in HCC**

Chair: *Assoc. Prof. Dr. Vesela Ivanova*



10:30 – 10:45 Application of gadolinium contrast agents in oncological imaging diagnostics

Assoc. Prof. Dr. Plamen Getsov

10:50 – 11:05 PET/CT with differently targeting radiopharmaceuticals in the detection and differential diagnosis of HCC with cirrhosis or chronic liver disease

Prof. Dr. Elena Piperkova

11:10 – 11:25 Advantages of ^{68}Ga -FAPI PET/CT in HCC

Prof. Dr. Sonya Sergieva

11:30 – 11:45 Well-differentiated hepatocellular lesions (WDHL) – the art of differentiation

Assoc. Prof. Dr. Ivan Ivanov

11:50 – 12:05 Macroscopic and histological levels of heterogeneity of HCC – unresolved definitions

Assoc. Prof. Dr. Vesela Ivanova

12:10 – 13:10 Symposium, supported by industry – Swixx Biopharma
Navigating the treatment of gastrointestinal tumors in the era of immunotherapy

Moderator: *Assoc. Prof. Dr. Asya Konsulova*

12:10 – 12:15 Opening and introduction

Assoc. Prof. Dr. Asya Konsulova

12:15 – 12:35 Personalized approach in the treatment of upper gastrointestinal tract carcinomas

Dr. Rositsa Krasteva

12:35 – 12:50 Modern therapeutic solutions for MSI-H/dMMR mCRC through the eyes of artificial and human intelligence

Dr. Tsvetan Yordanov

12:50 – 13:05 From science to clinical practice: local experience in the treatment of HCC

Dr. Manol Slavov

13:05 – 13:10 Discussion and summary

13:15 – 14:15 Lunch

14:15 – 15:55 THIRD PLENARY SESSION
Perioperative strategies in HCC

Chair: *Assoc. Prof. Dr. Elena Arabadzhieva*

14:15 – 14:30 Tools for assessing the risk of hepatic dysfunction after resection

Prof. Dr. Atanas Yonkov, Assoc. Prof. Dr. Elena Arabadzhieva

14:35 – 14:50 Preoperative assessment of metabolic risk factors in HCC with MASLD

Assoc. Prof. Dr. Tsonka Lukanova

14:55 – 15:10 Clinical decision for locoregional or systemic therapy in HCC – prognostic and predictive scores

Assoc. Prof. Dr. Marina Konakchieva

15:15 – 15:30 Perioperative systemic strategies in HCC – benefits and reservations

Dr. Krasimir Koynov



15:35 – 15:50 Nutritional screening and assessment in HCC
Prof. Dr. Darina Naydenova, Dr. Ivan Enev

15:55 – 16:20 FIRST JOINT BJCEN-BNCFMH SESSION

Integrative Oncology

Chair: *Dr. Petko Zagorchev*

15:55 – 16:05 SHISSO – European recommendations for supportive care in oncology
Dr. Ivan Enev

16:05 – 16:15 Supportive and palliative options of homeopathy in hepatocellular carcinoma
Dr. Petko Zagorchev

16:20 – 16:40 Coffee break

16:40 – 18:00 FOURTH PLENARY SESSION

Locoregional approaches in HCC

Chair: *Assoc. Prof. Dr. Valeria Hadzhiyska*

16:40 – 16:55 Role of TACE in the era of systemic therapy
Dr. Yana Sedef-Todorova

17:00 – 17:15 Non-thermal ablation techniques in HCC – benefits and reservations
Assoc. Prof. Dr. Aleksandar Katsarov

17:20 – 17:35 Percutaneous radiotherapy *versus* percutaneous ablation and TACE in HCC with single tumors or recurrence after ablation
Prof. Dr. Tatyana Hadzhieva, Dr. Doroteya Ivanova

17:40 – 17:55 SIRT *versus* locoregional and systemic therapies in HCC
Assoc. Prof. Dr. Valeria Hadzhiyska

18:00 – 19:00 Symposium, supported by industry – AstraZeneca

New Horizons in Personalized Oncology: Modern Therapeutic Strategies in Solid Tumors

Moderator: *Assoc. Prof. Dr. Dimitar Kalev*

18:00 – 18:15 Targeted Approaches Based on Endocrine Therapy in 2nd Line HR+ Breast Cancer
Dr. Vasil Popov

18:15 – 18:30 Modern Innovative Treatment of Advanced Hepatocellular and Resectable Gastric Cancer with Immunotherapeutic Regimens
Dr. Marcela Koleva

18:30 – 19:00 Are We Ready for the New Paradigm in the Treatment of Muscle-Invasive Bladder Cancer (MIBC)

- NIAGARA Regimen in Modern Oncological Practice

Dr. Velko Minchev

- Evolution of the Role of the Urologist in the Modern Treatment of MIBC

Prof. Dr. Kaloyan Davidov

19:30 Cocktail dinner

**3 October 2026, Saturday****09:00 – 10:40 FIFTH PLENARY SESSION****Surgical strategies in HCC**Chair: *Prof. Dr. Nikola Vladov*

09:00 – 09:15 Liver resection *versus* locoregional therapies in HCC with cirrhosis
Prof. Dr. Nikola Vladov, Dr. Tsvetan Trichkov

09:20 – 09:35 Is liver resection feasible in multifocal HCC
Prof. Dr. Nikolay Belev

09:40 – 09:55 Liver resection in HCC with thrombus in the suprahepatic inferior vena cava

Prof. Dr. Aleksandar Yuliyarov, Dr. Azize Saroglu

10:00 – 10:15 Minimally invasive liver surgery in HCC with cirrhosis and portal hypertension – benefits and reservations

Prof. Dr. Ivelin Takorov, Dr. Dimitria Valcheva

10:20 – 10:35 Liver transplantation in HCC – patient selection

*Prof. Dr. Vasil Mihaylov, Dr. Radoslav Kostadinov***10:40 – 11:00 Coffee break****11:00 – 12:30 SECOND JOINT BJCN-BNCMH SESSION****Bulgarian National Hub of the Mission on Cancer: Whose Mission Is Cancer?
From 108 Signatures to a Social Contract**Moderator: *MPharm Ivaylo Petrov***12:30 – 12:45 Official ceremony: Presentation of the Annual Award BJCN-MORE
– for contribution to Bulgarian clinical oncology****12:45 – 13:45 Lunch****13:45 – 14:45 POSTER SECTION BJCN-MORE – parade**Scientific jury, chairs: *Prof. Dr. Margarita Genova, DSc Lyubomir Balabanski***14:50 – 16:20 ORAL POSTER SESSION BJCN-MORE**Chairs: *Prof. Dr. Aleksandar Yuliyarov, DSc Lyubomir Balabanski***16:20 – 16:40 Coffee break****16:40 – 18:20 SIXTH PLENARY SESSION****Radiotherapy and systemic strategies in HCC**Chair: *Assoc. Prof. Dr. Asya Konsulova*

16:40 – 16:55 Percutaneous radiotherapy *versus* systemic therapy in advanced HCC with portal vein invasion

Prof. Dr. Iglia Mihaylova, Dr. Kamen Nedev

17:00 – 17:15 Radiotherapy combined with systemic therapy in unresectable HCC – benefits and reservations

Assoc. Prof. Dr. Veselin Popov

17:20 – 17:35 Systemic approaches in HCC with decompensated cirrhosis and post-transplant recurrence

Assoc. Prof. Dr. Asya Konsulova, Dr. Marchela Koleva

17:40 – 17:55 Adoptive cell therapy in HCC – concepts and clinical translations

Dr. Radoslav Mangalzhiev, Dr. Dimo Manov

18:00 – 18:15 Assessment of costs and clinical outcomes in liver transplantation for HCC

Prof. Dr. Maria Dimitrova, Assoc. Prof. Dr. Denitsa Stefanova, Corr. Mem. Prof. Georgi Momekov

18:20 – 18:30 Official Closing

19:00 Official Dinner

4 October 2026, Sunday

09:00 – 12:00 STRATEGIC BJCN SESSION

Evidence-based guidance models

Moderator: *Assoc. Prof. Dr. Dimitar Kalev*

With the participation of representatives from the expert boards of *BJCN-MOPE*

